Covered recipient · General Payments record
HARSHAD V AMIN
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$27,809.40
253 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,982.50 | 13 |
| Consulting Fee | $6,642.50 | 3 |
| Food and Beverage | $3,354.02 | 224 |
| Travel and Lodging | $1,170.46 | 5 |
| Education | $484.92 | 7 |
| Honoraria | $175.00 | 1 |
By paying entity
PY2020 · entire year · sorted by reported total
Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
HARSHAD V AMIN
NPI 1679807242 · CMS profile ID 724624
Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
PLANTATION, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- HARSHAD V AMIN, NPI 1679807242, CMS profile ID 724624. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). HARSHAD V AMIN, NPI 1679807242, CMS profile ID 724624. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- HARSHAD V AMIN, NPI 1679807242, CMS profile ID 724624, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 6 of 6; records 251–253 of 253 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1679807242?year=2020&recipient=provider&page=6#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
253 matching records · $27,809.40 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 251–253 of 253.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.44 | 01/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721000421 | CMS |
| Seagen Inc. | $95.00 | 01/03/2020 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 732456455 | CMS |
| Janssen Pharmaceuticals, Inc | $13.43 | 01/02/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719165131 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $631,397.59 | 109 |
| PY2024 | Principal investigator | $843,986.12 | 92 |
| PY2023 | Principal investigator | $838,551.38 | 209 |
| PY2022 | Principal investigator | $583,428.39 | 93 |
| PY2021 | Principal investigator | $405,294.96 | 86 |
| PY2020 | Principal investigator | $291,165.08 | 83 |
| PY2019 | Principal investigator | $148,284.54 | 40 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
109 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | PFIZER INC. | $11,200.95 | 12/31/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228747672 |
| Principal investigator 1 | PFIZER INC. | $9,722.70 | 12/12/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228731942 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,668.40 | 12/08/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091238 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,468.85 | 11/21/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146813 |
| Principal investigator 1 | PFIZER INC. | $4,750.00 | 11/14/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228738135 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $600.00 | 11/12/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415001 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $193.70 | 11/10/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091226 |
| Principal investigator 1 | PFIZER INC. | $9,289.20 | 11/04/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228730135 |
| Principal investigator 1 | Amgen Inc. | $750.00 | 10/24/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy | No dispute reported | 06/30/2026 | 1246639789 |
| Principal investigator 1 | PFIZER INC. | $1,200.00 | 10/21/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228741933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,300.00 | 10/14/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091204 |
| Principal investigator 1 | PFIZER INC. | $6,425.35 | 10/08/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228741047 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,930.00 | 10/06/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091193 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $140.00 | 10/02/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211416458 |
| Principal investigator 1 | Amgen Inc. | $1,350.00 | 09/23/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | No dispute reported | 06/30/2026 | 1246639793 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,200.00 | 09/22/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091182 |
| Principal investigator 1 | PFIZER INC. | $660.00 | 09/16/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228771240 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $160.00 | 09/15/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091167 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,362.40 | 09/15/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091171 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 09/12/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192144561 |
| Principal investigator 1 | PFIZER INC. | $1,216.35 | 09/03/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228750589 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $600.00 | 08/22/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211416460 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $600.00 | 08/22/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211418567 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,760.00 | 08/11/2025 | Non-covered Recipient Entity Boca Raton Cancer Research Global, BRCR Global | A Phase I,II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors | No dispute reported | 06/30/2026 | 1232932603 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,711.40 | 08/11/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091139 |
| Principal investigator 1 | PFIZER INC. | $1,262.25 | 08/02/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228768200 |
| Principal investigator 1 | PFIZER INC. | $1,675.35 | 07/30/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228720283 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 07/16/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228783529 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,900.00 | 07/14/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091485 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,711.40 | 07/07/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091129 |
| Principal investigator 1 | PFIZER INC. | $1,740.15 | 06/27/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228774887 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,755.00 | 06/22/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146834 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,300.00 | 06/16/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091475 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $486.53 | 06/16/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211415011 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $717.00 | 06/16/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211417843 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $54.06 | 06/16/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211420009 |
| Principal investigator 1 | PFIZER INC. | $3,850.00 | 06/14/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 | No dispute reported | 06/30/2026 | 1228777271 |
| Principal investigator 1 | PFIZER INC. | $1,800.00 | 06/14/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228791875 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211415013 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211415015 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,000.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211415776 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211416466 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $153.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211416468 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $153.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211416470 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,215.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211417845 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $153.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211417847 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $153.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211418573 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $153.00 | 06/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Randomized, Open-Label, Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD) Extended Schedule in Subjects With Lower Risk (IPSS Low or Intermediate-1) Myelodysplastic Syndromes (MDS) | No dispute reported | 06/30/2026 | 1211418575 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,362.40 | 06/09/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091471 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17.70 | 06/03/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192144574 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $900.00 | 06/02/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146837 |
| Principal investigator 1 | PFIZER INC. | $11,138.70 | 05/30/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228765591 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,015.55 | 05/29/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192148031 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $244.80 | 05/19/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091479 |
| Principal investigator 1 | Exelixis Inc. | $2,542.00 | 05/13/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379826 |
| Principal investigator 1 | Exelixis Inc. | $954.00 | 05/13/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379828 |
| Principal investigator 1 | Exelixis Inc. | $4,500.00 | 05/13/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379830 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,207.34 | 05/09/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211416464 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,711.40 | 05/05/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091440 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,631.15 | 05/02/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192144565 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 04/29/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228723514 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 04/28/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192144569 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,468.85 | 04/28/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192144579 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,890.00 | 04/28/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146817 |
| Principal investigator 1 | PFIZER INC. | $2,462.40 | 04/25/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228794605 |
| Principal investigator 1 | PFIZER INC. | $3,000.00 | 04/24/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228779687 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,300.00 | 04/14/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091429 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $600.00 | 04/14/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415009 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $500.00 | 04/08/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211420005 |
| Principal investigator 1 | PFIZER INC. | $722.25 | 04/05/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228779830 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,711.40 | 04/02/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091387 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 04/01/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211417841 |
| Principal investigator 1 | PFIZER INC. | $15,886.80 | 03/22/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228782763 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,468.85 | 03/21/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146821 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,468.85 | 03/21/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192148045 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 03/21/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211416462 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 03/19/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211415003 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $11,606.00 | 03/17/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091372 |
| Principal investigator 1 | PFIZER INC. | $500.00 | 03/14/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY | No dispute reported | 06/30/2026 | 1228782788 |
| Principal investigator 1 | PFIZER INC. | $600.00 | 03/14/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEADIN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600EMUTANT COLORECTAL CANCER | No dispute reported | 06/30/2026 | 1228796324 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 03/11/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192144558 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $9,997.09 | 03/06/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192148040 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 03/06/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211420003 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $320.00 | 03/04/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091306 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,340.90 | 02/27/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146809 |
| Principal investigator 1 | Amgen Inc. | $5,300.00 | 02/22/2025 | Non-covered Recipient Entity BOCA RATON CLINICAL RESEARCH GLOBAL SOUTH FLORIDA | Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-nave Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301) | No dispute reported | 06/30/2026 | 1246639755 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $500.00 | 02/20/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211417839 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,781.40 | 02/18/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091318 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,700.00 | 02/18/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091323 |
| Principal investigator 1 | PFIZER INC. | $5,875.35 | 02/14/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228769769 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,145.40 | 02/14/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211418571 |
| Principal investigator 1 | Exelixis Inc. | $4,725.00 | 02/07/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379822 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $300.00 | 02/07/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146829 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,740.77 | 02/05/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192148027 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $650.00 | 02/04/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091341 |
| Principal investigator 1 | Amgen Inc. | $236,284.52 | 01/27/2025 | Non-covered Recipient Entity BOCA RATON CLINICAL RESEARCH GLOBAL SOUTH FLORIDA | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy | No dispute reported | 06/30/2026 | 1246639753 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,711.40 | 01/27/2025 | Non-covered Recipient Entity Brcr Medical Center Inc | A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) | No dispute reported | 06/30/2026 | 1226091335 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,145.40 | 01/27/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211418569 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,023.83 | 01/27/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419257 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $600.00 | 01/24/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419261 |
| Principal investigator 1 | Exelixis Inc. | $675.00 | 01/20/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222379824 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 01/16/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192146825 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $600.00 | 01/16/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192148035 |
| Principal investigator 1 | PFIZER INC. | $2,397.60 | 01/15/2025 | Non-covered Recipient Entity BRCR Medical Center Inc | A PHASE 3 RANDOMIZED DOUBLEBLIND MULTICENTER STUDY OF ARV471 PF07850327 PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED DISEASE VERITAC3 | No dispute reported | 06/30/2026 | 1228800081 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $14,130.19 | 01/15/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415007 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,082.29 | 01/10/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419259 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $8,100.59 | 01/08/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | A PHASE 2, RANDOMIZED, OPEN-LABEL, PLATFORM STUDY UTILIZING A MASTER P | No dispute reported | 06/30/2026 | 1192148050 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,071.49 | 01/06/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211420007 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $9,631.08 | 01/03/2025 | Non-covered Recipient Entity BRCR MEDICAL CENTER INC | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415005 |